These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

827 related articles for article (PubMed ID: 26968206)

  • 1. Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC.
    Gabrielson A; Wu Y; Wang H; Jiang J; Kallakury B; Gatalica Z; Reddy S; Kleiner D; Fishbein T; Johnson L; Island E; Satoskar R; Banovac F; Jha R; Kachhela J; Feng P; Zhang T; Tesfaye A; Prins P; Loffredo C; Marshall J; Weiner L; Atkins M; He AR
    Cancer Immunol Res; 2016 May; 4(5):419-30. PubMed ID: 26968206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association With Vascular Formation.
    Itoh S; Yoshizumi T; Yugawa K; Imai D; Yoshiya S; Takeishi K; Toshima T; Harada N; Ikegami T; Soejima Y; Kohashi K; Oda Y; Mori M
    Hepatology; 2020 Dec; 72(6):1987-1999. PubMed ID: 32112577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy.
    Umemoto Y; Okano S; Matsumoto Y; Nakagawara H; Matono R; Yoshiya S; Yamashita Y; Yoshizumi T; Ikegami T; Soejima Y; Harada M; Aishima S; Oda Y; Shirabe K; Maehara Y
    J Gastroenterol; 2015 Jan; 50(1):65-75. PubMed ID: 24509608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma.
    Huang CY; Wang Y; Luo GY; Han F; Li YQ; Zhou ZG; Xu GL
    J Immunother; 2017; 40(9):323-333. PubMed ID: 29028787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver-infiltrating CD8(+) lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma.
    Ramzan M; Sturm N; Decaens T; Bioulac-Sage P; Bancel B; Merle P; Tran Van Nhieu J; Slama R; Letoublon C; Zarski JP; Jouvin-Marche E; Marche PN; Leroy V
    Liver Int; 2016 Mar; 36(3):434-44. PubMed ID: 26215124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of the Immunoscore as prognostic tool for hepatocellular carcinoma.
    Petrizzo A; Buonaguro L
    J Immunother Cancer; 2016; 4():71. PubMed ID: 27879973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased expression of interleukin-36α correlates with poor prognosis in hepatocellular carcinoma.
    Pan QZ; Pan K; Zhao JJ; Chen JG; Li JJ; Lv L; Wang DD; Zheng HX; Jiang SS; Zhang XF; Xia JC
    Cancer Immunol Immunother; 2013 Nov; 62(11):1675-85. PubMed ID: 24061617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.
    Gao Q; Qiu SJ; Fan J; Zhou J; Wang XY; Xiao YS; Xu Y; Li YW; Tang ZY
    J Clin Oncol; 2007 Jun; 25(18):2586-93. PubMed ID: 17577038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of immune infiltration in sarcomatoid hepatocellular carcinoma.
    Luo C; Xin H; Yin D; Zhao T; Hu Z; Zhou Z; Sun R; Yao N; Sun Q; Fan J; Huang X; Zhou J; Zhou S
    Aging (Albany NY); 2021 Jun; 13(11):15126-15138. PubMed ID: 34081621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Foxp3-positive tumor-infiltrating lymphocytes in the histologic features and clinical outcomes of hepatocellular carcinoma.
    Mathai AM; Kapadia MJ; Alexander J; Kernochan LE; Swanson PE; Yeh MM
    Am J Surg Pathol; 2012 Jul; 36(7):980-6. PubMed ID: 22446942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-infiltrating FoxP3+ Tregs and CD8+ T cells affect the prognosis of hepatocellular carcinoma patients.
    Huang Y; Wang FM; Wang T; Wang YJ; Zhu ZY; Gao YT; Du Z
    Digestion; 2012; 86(4):329-37. PubMed ID: 23207161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy.
    Lim YJ; Koh J; Kim K; Chie EK; Kim B; Lee KB; Jang JY; Kim SW; Oh DY; Bang YJ; Ha SW
    Radiother Oncol; 2015 Oct; 117(1):165-70. PubMed ID: 26235847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping.
    Jesinghaus M; Steiger K; Slotta-Huspenina J; Drecoll E; Pfarr N; Meyer P; Konukiewitz B; Bettstetter M; Wieczorek K; Ott K; Feith M; Langer R; Weichert W; Specht K; Boxberg M
    Oncotarget; 2017 Jul; 8(29):46756-46768. PubMed ID: 28657901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of tumor PD-L1 expression combined with CD8
    Wang Q; Lou W; Di W; Wu X
    Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma.
    Nowicki TS; Akiyama R; Huang RR; Shintaku IP; Wang X; Tumeh PC; Singh A; Chmielowski B; Denny C; Federman N; Ribas A
    Cancer Immunol Res; 2017 Feb; 5(2):118-126. PubMed ID: 28039162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The predictive value of centre tumour CD8⁺ T cells in patients with hepatocellular carcinoma: comparison with Immunoscore.
    Sun C; Xu J; Song J; Liu C; Wang J; Weng C; Sun H; Wei H; Xiao W; Sun R; Tian Z
    Oncotarget; 2015 Nov; 6(34):35602-15. PubMed ID: 26415232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Role of Tumoral PD-L1 and IDO1 Expression, and Intratumoral CD8+ and FoxP3+ Lymphocyte Infiltrates in 132 Primary Cutaneous Merkel Cell Carcinomas.
    Donizy P; Wu CL; Kopczynski J; Pieniazek M; Biecek P; Ryś J; Hoang MP
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional CD3
    Lv S; Wang S; Qiao G; Wang X; Zhou X; Yan F; Li Y; Wang S; Morse MA; Hobeika A; Ren J; Lyerly HK
    Clin Breast Cancer; 2019 Oct; 19(5):e617-e623. PubMed ID: 31101455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases.
    Uruga H; Bozkurtlar E; Huynh TG; Muzikansky A; Goto Y; Gomez-Caraballo M; Hata AN; Gainor JF; Mark EJ; Engelman JA; Lanuti MD; Mino-Kenudson M
    J Thorac Oncol; 2017 Mar; 12(3):458-466. PubMed ID: 27815126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
    Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
    Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.